DPY19L2P2

Across TCGA pan-cancer cohorts, DPY19L2P2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DPY19L2P2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DPY19L2P2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DPY19L2P2 expression acts as an unfavorable survival marker.

BLCA, LUSC, and UCEC are the cancer types where DPY19L2P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.120	0.474	<.001	12	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DPY19L2P2–BLCA (DFS)

Open the BLCA breakdown →